MedTrace Logo

18F-NaF PET Imaging for Bone Scintigraphy

NCT01930812 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 286

Last updated 2019-04-25

No results posted yet for this study

Summary

The purpose of this study is to compare, in patients with prostate or breast cancer, the accuracy of 18F-NaF PET imaging to 99mTc whole body bone scans with single-photon emission computed tomography (SPECT).

Conditions

  • Bone Metastases From Breast or Prostate Cancer

Interventions

PROCEDURE

NaF PET/CT Imaging

Diagnostic imaging test that is considered investigational

PROCEDURE

99mTc-medronate whole body bone scan with SPECT

99mTc-medronate whole body bone scan with SPECT imaging. Note, that this is a standard procedure in this patient population and thus is not considered investigational.

DRUG

18F-Sodium Fluoride (NaF)

A single radioactive dose of 18F-NaF (185-370 MBq) is intravenously administered to subject 60 minutes prior to PET/CT imaging to evaluate whether or not subject has bone metastasis from advanced prostate or breast cancer. Entire procedure from injection to scan completion will take about 2.25 hours

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • British Columbia Cancer Agency

    lead OTHER

Principal Investigators

  • Francois Benard, MD · British Columbia Cancer Agency

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2017-03-31
Completion
2019-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01930812 on ClinicalTrials.gov